argenx SE (EBR:ARGX)
771.00
-21.20 (-2.68%)
At close: Dec 5, 2025
argenx SE Revenue
argenx SE had revenue of $1.15B USD in the quarter ending September 30, 2025, with 95.51% growth. This brings the company's revenue in the last twelve months to $3.68B, up 92.98% year-over-year. In the year 2024, argenx SE had annual revenue of $2.25B with 77.22% growth.
Revenue (ttm)
$3.68B
Revenue Growth
+92.98%
P/S Ratio
15.03
Revenue / Employee
$2.30M
Employees
1,599
Market Cap
47.19B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.25B | 979.61M | 77.22% |
| Dec 31, 2023 | 1.27B | 827.58M | 187.66% |
| Dec 31, 2022 | 441.01M | -87.25M | -16.52% |
| Dec 31, 2021 | 528.27M | 466.31M | 752.59% |
| Dec 31, 2020 | 61.96M | -30.85M | -33.24% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UCB SA | 6.85B |
| Financière de Tubize | 13.26K |
| Fagron NV | 918.75M |
| Ion Beam Applications | 585.76M |
| Nyxoah | 5.64M |
| Onward Medical | 2.72M |
| Hyloris Pharmaceuticals | 8.46M |
| Sequana Medical NV | 105.50K |
argenx SE News
- 1 day ago - ARGX: Morgan Stanley Raises Price Target to $1110, Maintains Overweight Rating | ARGX Stock News - GuruFocus
- 3 days ago - ARGX Quantitative Stock Analysis - Benjamin Graham - Nasdaq
- 7 days ago - If You Invested $1000 In argenx Stock 5 Years Ago, You Would Have This Much Today - Benzinga
- 7 days ago - Looking Into argenx SE's Recent Short Interest - Benzinga
- 9 days ago - argenx: Sights Set On $1,000 - Seeking Alpha
- 11 days ago - This Argenx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
- 11 days ago - ARGX Downgraded by Wolfe Research to 'Peer Perform' | ARGX Stock News - GuruFocus
- 15 days ago - Guru Fundamental Report for ARGX - Benjamin Graham - Nasdaq